ReGeneraTing Agents (RGTA
CACIPLIQ
finger
functional recovery
heparan sulfate mimetic
matrix therapy
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
04
10
2018
revised:
19
01
2019
accepted:
24
01
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
19
4
2019
Statut:
epublish
Résumé
CACIPLIQ20
Identifiants
pubmed: 30997049
doi: 10.1002/ccr3.2054
pii: CCR32054
pmc: PMC6452499
doi:
Types de publication
Case Reports
Langues
eng
Pagination
619-625Déclaration de conflit d'intérêts
DB has financial interest as inventor of the patented RGTA® technology.
Références
Int Wound J. 2016 Feb;13(1):35-8
pubmed: 24618185
Ann Chir Plast Esthet. 2010 Oct;55(5):421-8
pubmed: 20869155
J Biol Chem. 2005 Sep 23;280(38):32792-800
pubmed: 16014624
Adv Wound Care (New Rochelle). 2018 Mar 1;7(3):77-94
pubmed: 29644145
Clin Case Rep. 2018 Sep 14;6(11):2061-2069
pubmed: 30455892
J Fr Ophtalmol. 2013 Nov;36(9):740-7
pubmed: 23958066
Wound Repair Regen. 2011 Jul-Aug;19(4):505-14
pubmed: 21649786
J Biomed Mater Res A. 2007 Jan;80(1):75-84
pubmed: 16958049
Clin Case Rep. 2019 Feb 17;7(4):619-625
pubmed: 30997049
Diabetes. 2012 Oct;61(10):2633-41
pubmed: 22721969
Wound Repair Regen. 2009 Nov-Dec;17(6):840-52
pubmed: 19903305
Int J Low Extrem Wounds. 2016 Mar;15(1):63-7
pubmed: 26933115
Glycoconj J. 2017 Jun;34(3):325-338
pubmed: 27924424
Ann Chir Plast Esthet. 2010 Oct;55(5):413-20
pubmed: 20888111